Bacterial expression and characterization of an anti-CD22 single-chain antibody fragment

Mikiewicz, Diana; Łukasiewicz, Natalia; Zieliński, Marcin; Cecuda-Adamczewska, Violetta; Bierczyńska-Krzysik, Anna; Romanik-Chruścielewska, Agnieszka; Kęsik-Brodacka, Małgorzata

doi:10.1016/j.pep.2020.105594

Cited by 4 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD22 is a transmembrane protein specific to B cells and is present in 60–80% of all B-cell lymphomas and leukemias. The anti-CD22 scFv proved to be specific in CD22+ lymphoma cell lines [ 139 ]. Likewise, Morali-Kalbolandi et al developed an anti-CD123 scFv, a molecule that is overexpressed in leukemic stem cells.…”

Section: Applications Of Scfvsmentioning

confidence: 99%

Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy

Muñoz-López

Ribas‐Aparicio

Becerra-Báez

et al. 2022

Cancers

View full text Add to dashboard Cite

Cancer remains a public health problem worldwide. Although conventional therapies have led to some excellent outcomes, some patients fail to respond to treatment, they have few therapeutic alternatives and a poor survival prognosis. Several strategies have been proposed to overcome this issue. The most recent approach is immunotherapy, particularly the use of recombinant antibodies and their derivatives, such as the single-chain fragment variable (scFv) containing the complete antigen-binding domains of a whole antibody that successfully targets tumor cells. This review describes the recent progress made with scFvs as a cancer diagnostic and therapeutic tool, with an emphasis on preclinical approaches and their potential use in clinical trials.

show abstract

Section: Applications Of Scfvsmentioning

confidence: 99%

Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy

Muñoz-López

Ribas‐Aparicio

Becerra-Báez

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…The choice of expression system to produce an active biopharmaceutical substance is crucial in the development of manufacturing technologies [20]. Therefore, we explore the viability of E. coli-based expression systems which allow rapid bacterial growth, simple scaling of the process and are usually economically viable.…”

Section: Introductionmentioning

confidence: 99%

Optimization of Expression and Purification of Schistosoma mansoni Antigens in Fusion with Rhizavidin

et al. 2021

View full text Add to dashboard Cite

Schistosomiasis causes significant morbidity and mortality. Vaccine efforts to date indicate the need to increase the immunogenicity of Schistosoma antigens. The multiple antigen-presenting system, whereby proteins are genetically fused to rhizavidin and affinity linked to biotinylated templates, enables the generation of robust immune responses. The objective of this work was to express and purify the S. mansoni antigens, SmTSP-2 and SmCD59.2, in fusion with rhizavidin. The fusion with rhizavidin greatly decreased the expression level of rSmTSP-2, but not rSmCD59.2, and both were expressed in the insoluble fraction, requiring optimization of culture conditions. Evaluation of different E. coli strains and media showed that BL21-DE3 cultured in Terrific Broth provided the highest expression levels of both proteins. Investigation of a range of time and temperature of induction showed that E. coli strains expressing rRzv:SmTSP-2 and rRzv:SmCD59.2 showed the highest protein production at 23 °C for 15 h. Recombinant proteins were purified by a single step of affinity chromatography allowing isolation of these proteins in high concentration and purity. The optimization process increased final soluble protein yield of rRzv:SmTSP-2 by fourfold and rRzv:SmCD59.2 by tenfold, providing ~ 20 mg/L of each protein. Optimized fusion protein production will allow antigen use in biotin-rhizavidin affinity platforms.

show abstract

Prokaryotic expression, purification, and the in vitro and in vivo protection study of dehydrin WDHN2 from Triticum aestivum

Zhang,

Wu,

et al. 2024

Protoplasma

View full text Add to dashboard Cite

Bacterial expression and characterization of an anti-CD22 single-chain antibody fragment

Cited by 4 publications

References 17 publications

Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy

Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy

Optimization of Expression and Purification of Schistosoma mansoni Antigens in Fusion with Rhizavidin

Prokaryotic expression, purification, and the in vitro and in vivo protection study of dehydrin WDHN2 from Triticum aestivum

Contact Info

Product

Resources

About